Guido J. Neels
Guido J. Neels's purchase track record
Guido J. Neels has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/28/2026 | ELUT | $53K | -4.8% | -16.2% | +4.9% |
| 8/16/2023 | AXGN | $61K | +1.9% | +75.2% | +13.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Elutia Secures $8M from Boston Scientific, Funds Through 2029. Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Axogen Receives New Analyst Coverage and Valuation Upside. Axogen has attracted new analyst coverage from Robinhood and B of A Securities, both issuing bullish notes and setting price targets around $52. A Yahoo analysis suggests the stock may be about 26% undervalued on cash‑flow grounds, while the company has fallen 22.6% in the past month. These developments highlight renewed investor interest and potential upside relative to recent price action.
Transaction History
| TELA | ▲ Buy | Grant | 11,925 | $0 | 6/9/2026 | View on chart |
| TELA | ▲ Buy | Grant | 11,675 | $0 | 6/9/2026 | View on chart |
| BVS | ▲ Buy | Option Exercise | 32,282 | $0 | 6/2/2026 | View on chart |
| ELUT | ▲ Buy | Open Market | 20,000 | $21K | 1/30/2026 | View on chart |
| ELUT | ▲ Buy | Open Market | 15,000 | $16K | 1/29/2026 | View on chart |
| ELUT | ▲ Buy | Open Market | 15,000 | $16K | 1/28/2026 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 6,250 | — | 12/10/2025 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 6,250 | — | 12/1/2025 | View on chart |
| AXGN | ▼ Sell | Open Market | 4,073 | $43K | 6/9/2025 | View on chart |
| BVS | ▲ Buy | Option Exercise | 26,493 | $0 | 6/2/2025 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 11,904 | $0 | 9/1/2024 | View on chart |
| BVS | ▲ Buy | Option Exercise | 30,400 | $0 | 6/7/2024 | View on chart |
| AXGN | ▲ Buy | Grant | 10,653 | — | 6/6/2024 | View on chart |
| AXGN | ▲ Buy | Open Market | 10,000 | $61K | 8/16/2023 | View on chart |
| BVS | ▲ Buy | Option Exercise | 16,648 | $0 | 6/6/2023 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 6,459 | $0 | 6/1/2023 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 3,036 | $0 | 6/1/2022 | View on chart |
| BVS | ▲ Buy | Option Exercise | 2,700 | — | 4/1/2022 | View on chart |
| BVS | ▲ Buy | Option Exercise | 9,000 | — | 2/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Craig-Hallum initiates coverage on TELA Bio with $2 target
Craig-Hallum has started tracking TELA Bio, assigning a price target of $2. This new analyst note aligns with the current average analyst target of $2.08. The stock is currently trading above its 52-week low of $0.50, with recent technical indicators showing momentum near the upper end of its recent range.
Craig-Hallum initiates coverage on TELA Bio with $2 target. Craig-Hallum has started tracking TELA Bio, assigning a price target of $2. This new analyst note aligns with the current average analyst target of $2.08. The stock is currently trading above its 52-week low of $0.50, with recent technical indicators showing momentum near the upper end of its recent range.